Psoriasis is linked to heart attack, diabetes, high blood pressure, and fatty liver. What the evidence shows, which screening is advised, and whether treating the skin lowers the risk.

Does psoriasis affect the heart? For many patients, the question is never raised during a visit focused on itchy, scaling plaques. Yet psoriasis is increasingly recognized as a systemic inflammatory disease, and the immune signals that drive plaques in the skin are also linked to inflammation in blood vessels, fat tissue, and the liver [1]. Large population studies associate psoriasis, particularly when severe, with higher rates of heart attack, cardiovascular death, diabetes, and related metabolic conditions. This article reviews what that evidence shows, what it does not show, and whether treating the skin can lower the risk.
Psoriasis is a chronic immune-mediated disease that affects an estimated 2 to 3 percent of the population in the United States [10]. Its best-known companion outside the skin is psoriatic arthritis, but a growing body of research links psoriasis to cardiometabolic disease, a term that groups heart disease, stroke, diabetes, high blood pressure, abnormal cholesterol, and fatty liver disease [1]. The common ground is chronic inflammation.
In psoriasis, immune cells release signalling proteins such as tumour necrosis factor, interleukin-17, interleukin-23, and interleukin-6. A review in the Journal of the American College of Cardiology describes how these pathways, together with activated platelets and myeloid cells, are linked to inflammation of the artery wall and to atherosclerosis, the build-up of fatty plaque inside arteries [10]. The genetic and immune roots of this circuit are described in more detail in What Are the Roots of My Psoriasis?
The modern discussion began with a 2006 study in JAMA that compared more than 130,000 people with psoriasis and over 550,000 people without it, using United Kingdom general practice records [2]. After adjustment for high blood pressure, diabetes, cholesterol, smoking, age, sex, and body mass index, psoriasis remained an independent risk factor for myocardial infarction, the medical term for a heart attack. The relative risk was highest in young people with severe disease. A 30-year-old with severe psoriasis had about three times the risk of a heart attack of a peer without psoriasis, while for a 60-year-old the increase was about 36 percent [2].
A follow-up study from the same database examined deaths. Severe psoriasis, defined by the need for systemic therapy, was associated with a 57 percent higher risk of cardiovascular death after accounting for traditional risk factors. This corresponded to about one additional cardiovascular death per 283 patients each year, and the relative increase was again most pronounced at younger ages [3].
The risk is not evenly distributed. In a United Kingdom cohort of more than 138,000 people with psoriasis, the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) was about 8 percent higher in people with psoriasis who were not prescribed systemic medication, but about 42 percent higher in those with severe disease requiring it [4]. A cardiology review summarizes the overall picture as up to a 50 percent higher likelihood of cardiovascular disease, rising with skin severity [10]. For most people with limited plaques, the absolute increase in risk is small; for those with extensive disease, it becomes clinically meaningful.
Imaging studies suggest that the inflammation reaches the vessels themselves. In a study of relatively young adults with mostly mild to moderate psoriasis and low traditional cardiovascular risk, higher Psoriasis Area and Severity Index (PASI) scores were associated with greater inflammation in the aorta on positron emission tomography, independent of age, sex, and Framingham risk score [9]. The same patients showed signs of activated neutrophils, a type of white blood cell, in the bloodstream [9].
Cardiovascular risk does not travel alone. Meta-analyses of observational studies have found that people with psoriasis are more likely to have several conditions that independently raise cardiovascular risk:
In each of these analyses, the association was stronger in more severe psoriasis [5, 6, 7, 8]. The direction of cause is not fully settled. Shared inflammatory pathways, genetic susceptibility, and common risk factors such as excess weight and smoking are all thought to contribute [1]. In practical terms, a person with moderate to severe psoriasis is more likely to be carrying several cardiovascular risk factors at once, some of which cause no symptoms until they are measured.
Psoriasis care is often divided. The dermatologist manages the skin, the family physician manages blood pressure and cholesterol, and the connection between the two can fall through the gap. Standard cardiovascular risk calculators do not include psoriasis, so a young adult with severe skin disease and otherwise normal numbers may be classified as low risk. Visits focused on itch, flares, and medication refills leave little time for a conversation about the heart.
This gap is now recognized in guidelines. The 2019 joint guideline of the American Academy of Dermatology and the National Psoriasis Foundation on psoriasis comorbidities recommends that dermatologists inform patients about their increased cardiovascular risk, and that people with moderate to severe psoriasis undergo periodic screening of blood lipids and blood sugar [11]. The 2018 cholesterol guideline of the American College of Cardiology and the American Heart Association lists psoriasis as a risk-enhancing condition, which can favour earlier consideration of cholesterol-lowering statin therapy [10, 11].
This is the question most patients ask once they learn about the connection. The honest answer is that it is possible, but it has not been proven. The evidence comes in three layers, and they do not all point in the same direction [10].
Several large cohort studies suggest that systemic treatment is associated with fewer cardiovascular events. In a Kaiser Permanente Southern California cohort of 8,845 patients, those treated with tumour necrosis factor (TNF) inhibitors had about half the risk of heart attack of patients treated with topical therapy alone, with incidence rates of 3.05 versus 6.73 per 1,000 patient-years [12]. In a Danish nationwide cohort of 6,902 patients with severe psoriasis, methotrexate was associated with a 47 percent lower rate of cardiovascular death, heart attack, or stroke compared with other therapies, and TNF inhibitors with a 54 percent lower rate. Oral retinoids showed no such benefit [13].
Coronary imaging adds a further signal. In a prospective study of 121 patients with moderate to severe psoriasis, one year of biologic therapy was associated with a 6 percent reduction in non-calcified coronary plaque burden, the inflammation-driven type of plaque considered higher risk, whereas plaque progressed slowly in patients not receiving biologics [14].
The caveat: observational studies cannot fully separate the effect of a drug from the characteristics of the people who receive it. Patients selected for biologic therapy may differ in overall health, follow-up, and access to care from those treated with creams alone, a problem known as confounding by indication. These studies generate hypotheses; they do not confirm cause and effect.
Randomized trials, which avoid this bias, have been less encouraging in the short term. In a trial of 97 patients, neither adalimumab, a TNF inhibitor, nor phototherapy reduced inflammation in the aorta after 12 weeks, and no change was seen after 52 weeks of adalimumab, although both treatments lowered blood markers of inflammation such as C-reactive protein and interleukin-6 [15]. A placebo-controlled trial of secukinumab, an interleukin-17A inhibitor, likewise showed a neutral effect on aortic inflammation and cardiometabolic blood markers over 52 weeks [16].
Safety data are reassuring. A meta-analysis of 38 randomized trials involving 18,024 patients found no significant increase in major adverse cardiovascular events with licensed biologic therapies during the trial periods [17]. None of these trials, however, was designed or long enough to show whether treatment prevents heart attacks or strokes. Answering that question would require large outcome trials lasting several years [10].
Cardiology trials support the principle while warning against oversimplification. In the CANTOS trial, canakinumab, an antibody that blocks interleukin-1 beta, lowered the rate of recurrent cardiovascular events in people with a previous heart attack and persistently elevated C-reactive protein, offering proof that reducing inflammation can protect the heart [18]. In the CIRT trial, by contrast, low-dose methotrexate did not reduce inflammatory markers or cardiovascular events in people with coronary disease and diabetes or metabolic syndrome [19].
Neither trial enrolled people selected for psoriasis, so the results cannot be transferred directly. Together, they suggest that the specific pathway targeted, and the presence of active inflammation to treat, both matter. Controlling psoriasis may well help the heart, but it is not a substitute for managing blood pressure, cholesterol, blood sugar, and smoking.
Treat psoriasis well for its own sake. Adequate control of psoriasis is worthwhile on its own merits, for comfort, sleep, mood, and quality of life. A possible cardiovascular benefit is a reasonable additional consideration in moderate to severe disease, but it is not, by itself, an established reason to choose a particular medication. Options range from topical therapy and phototherapy to biologic and advanced small-molecule therapy.
Know the numbers. Blood pressure, weight and waist circumference, cholesterol, and fasting blood sugar or hemoglobin A1C are worth checking regularly, particularly in moderate to severe psoriasis [11]. Results are best reviewed with the family physician, who manages most cardiovascular prevention.
Address the risk factors that can be changed. Not smoking, regular physical activity, and weight management reduce cardiovascular risk for everyone, and they matter more when psoriasis adds to the baseline risk.
Tell every physician about psoriasis. Because standard risk calculators do not include psoriasis, family physicians and cardiologists benefit from knowing about the diagnosis and its severity when estimating risk and considering statin therapy [10, 11].
Measure severity objectively. Standardized measures such as body surface area and PASI help identify patients whose disease warrants systemic therapy and closer cardiometabolic monitoring.
Moderate to severe psoriasis is managed at the Centre for Medical and Surgical Dermatology through the Immune-Mediated Skin Disease Program, where treatment is matched to the underlying disease pathway, related health conditions, and personal goals. Patients may request a consultation, and physicians may refer a patient directly.
This article is intended for educational purposes and does not replace professional medical advice. Please consult your dermatologist for personalized recommendations.
Your feedback helps us improve our news and clinical insights

From medical dermatology to surgical procedures, our clinic provides comprehensive care for all skin, hair, and nail conditions.